Figures & data
Figure 1 Model structure.
![Figure 1 Model structure.](/cms/asset/5ae56d35-c962-4c65-8320-ada3fb73b936/dcop_a_12163732_f0001_c.jpg)
Table 1 Baseline Characteristics of Two Trial Cohort
Table 2 FEV1 in Liters Improvement in Two Cohorts
Table 3 Results of Whole Life Simulation of IND/GLY vs SAL/FLU
Figure 2 Probability sensitivity analysis of IND/GLY vs SAL/FLU. We showed the results of probability sensitivity analysis (PSA) of IND/GLY vs SAL/FLU in this scatter plot. Each scatter represents an iteration in this model with different incremental costs and QALYs in PSA. This figure showed in most iterations, IND/GLY is with lower costs and longer QALYs than SAL/FLU. We concluded that IND/GLY is with dominate cost-effectiveness than SAL/FLU.
![Figure 2 Probability sensitivity analysis of IND/GLY vs SAL/FLU. We showed the results of probability sensitivity analysis (PSA) of IND/GLY vs SAL/FLU in this scatter plot. Each scatter represents an iteration in this model with different incremental costs and QALYs in PSA. This figure showed in most iterations, IND/GLY is with lower costs and longer QALYs than SAL/FLU. We concluded that IND/GLY is with dominate cost-effectiveness than SAL/FLU.](/cms/asset/ee920bb3-81e0-4d0e-b421-e20b78c03b1b/dcop_a_12163732_f0002_c.jpg)
Table 4 Results of Whole Life Simulation of IND/GLY vs Tiotropium
Figure 3 Probability sensitivity analysis of IND/GLY vs tiotropium. We showed the results of probability sensitivity analysis (PSA) of IND/GLY vs tiotropium in this scatter plot. Each scatter represents an iteration in this model with different incremental costs and QALYs in PSA. As IND/GLY can bring longer QALYs but cost more. We need to figure out the probability of scatters to be cost-effective under different threshold.
![Figure 3 Probability sensitivity analysis of IND/GLY vs tiotropium. We showed the results of probability sensitivity analysis (PSA) of IND/GLY vs tiotropium in this scatter plot. Each scatter represents an iteration in this model with different incremental costs and QALYs in PSA. As IND/GLY can bring longer QALYs but cost more. We need to figure out the probability of scatters to be cost-effective under different threshold.](/cms/asset/06d2531f-5d49-476a-8caa-bea4ffa4f52a/dcop_a_12163732_f0003_c.jpg)
Figure 4 The probability of being cost-effective in PSA of IND/GLY vs tiotropium. This figure showed the probability of iterations in PSA being accepted as cost-effective under different threshold. In our study, we selected 70,000 CNY as willingness-to-pay threshold as we mentioned fully in Method section. We can see the probability of cost-effectiveness of IND/GLY comparing with tiotropium is 50–60%.
![Figure 4 The probability of being cost-effective in PSA of IND/GLY vs tiotropium. This figure showed the probability of iterations in PSA being accepted as cost-effective under different threshold. In our study, we selected 70,000 CNY as willingness-to-pay threshold as we mentioned fully in Method section. We can see the probability of cost-effectiveness of IND/GLY comparing with tiotropium is 50–60%.](/cms/asset/42b15df1-d9c0-42b7-8e23-c4cef2e047a5/dcop_a_12163732_f0004_c.jpg)